Fosun Acquires China Rights to Dove's Oral Thrombocytopenia Drug

Fosun Pharma acquired China rights to an thrombocytopenia candidate from a subsidiary of Dova Pharma, AkaRx. Avatrombopag is an oral drug candidate for thrombocytopenia (low platelet count) in patients with chronic liver disease. In a US Phase III trial, avatrombopag met all primary endpoints, and Dova expects to hear whether the FDA will grant US approval of the drug by May 21, 2018 . The Fosun-Dova agreement includes an undisclosed upfront payment, milestone payments, and a fixed transfer price for product supplied. Fosun will also support additional indication applications for avatrombopag in China. More details....

Stock Symbols: (SHA: 600196; HK: 02196) (NSDQ: DOVA)

Share this with colleagues:

Original Article: Fosun Acquires China Rights to Dove's Oral Thrombocytopenia Drug

More From BioPortfolio on "Fosun Acquires China Rights to Dove's Oral Thrombocytopenia Drug"